meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - colorectal cancer (mCRC)
2
mCRC - (neo)adjuvant (NA)
mCRC - 1st line (L1)
5
mCRC - 2nd line (L2)
6
endometrial cancer
10
All treatments
chemotherapy
non platinum-based chemotherapy
nucleoside analogues (pyrimidine/purine)
capecitabine
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab
atezolizumab plus cometinib
avelumab based treatment
avelumab alone
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs nucleoside analogues (pyrimidine/purine)
vs capecitabine
vs Standard of Care (SoC)
vs non active control
vs BSC
vs VEGF(R) inhibitor
vs bevacizumab based treatment
vs placebo plus bevacizumab
vs regorafenib
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
summary
GRADE
treatment
patients
risk of bias
overview
numeric
bar chart
forest plot
medians
frequency on treatment
benefit risk analysis
Study
study type
RCT
OBS
RCT + OBS
Pathology
T1
T0
Patients
sample sizes
ROB
Results
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open